Saturday 17 October 2026
Export LFST’s income statement to Excel — free account
LifeStance Health Group, Inc.
LFST Healthcare Medical Care Facilities
LifeStance Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 13.9% from fiscal 2024. In the quarter to June 2026, revenue grew 26.1%, EPS grew 700.0%, free cash flow grew 55.2% and total debt fell 5.08%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
11.74
0.63
−5.09%
Follow LFST
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
283.87 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Piotroski F-Score |
8 | 6 | 4 | 4 | 5 | — | — | — |
Altman Z-Score |
2.65 | 2.54 | 2.25 | 1.35 | 4.59 | — | — | — |
P/S ratio |
1.91 | 2.23 | 2.75 | 1.92 | 4.67 | 14.96 | 14.96 | — |
P/FCF ratio |
24.70 | 32.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
1.71 | 1.16 | 0.50 | 1.10 | 3.15 | 1.87 | (2.60) | — |
Beneish M-Score |
(2.96) | (2.83) | (2.73) | (2.75) | (2.82) | (1.48) | — | — |
P/Operating CF |
47.21 | 44.84 | 172.84 | 45.99 | 101.78 | 675.27 | 675.27 | — |
P/B ratio |
1.79 | 1.93 | 2.03 | 1.09 | 2.02 | 7.01 | 7.01 | — |
Price to Tangible BV |
54.35 | 0.00 | 0.00 | 0.00 | 77.70 | 0.00 | 0.00 | — |
EV/Sales |
1.92 | 2.33 | 2.94 | 2.06 | 4.69 | 15.74 | 15.74 | — |
EV/EBITDA |
34.22 | 71.20 | 0.00 | 0.00 | 0.00 | 147.69 | 147.69 | — |
EV/Operating CF |
18.71 | 27.22 | (183.86) | 33.50 | 332.00 | (486.93) | (486.93) | — |
EV/FCF |
24.86 | 34.07 | (54.08) | (66.82) | (36.76) | (166.98) | (166.98) | — |
Quick Ratio |
1.37 | 1.25 | 1.01 | 1.19 | 1.92 | 0.82 | 0.40 | — |
Current Ratio |
1.65 | 1.37 | 1.11 | 1.33 | 2.28 | 1.00 | 0.50 | — |
Net Debt/EBITDA |
0.22 | 3.05 | (1.89) | (0.84) | (0.04) | 7.24 | 3.44 | — |
Debt/Assets |
12.07% | 13.21% | 13.28% | 10.35% | 8.17% | 23.10% | 28.25% | 0.00% |
Debt/Equity |
0.17 | 0.19 | 0.20 | 0.15 | 0.10 | 0.36 | (0.48) | — |
Asset Turnover |
0.66 | 0.59 | 0.49 | 0.42 | 0.38 | 0.41 | 1.51 | — |
Operating CF/Net income |
15.12 | (1.87) | 0.09 | (0.24) | (0.03) | 0.03 | (0.29) | — |
Capex/Depreciation |
(0.65) | (0.30) | (0.49) | (1.11) | (1.69) | (1.19) | (2.10) | — |
Interest Coverage |
2.07 | (1.19) | (8.91) | (10.55) | (7.36) | 0.70 | 2.82 | — |
| 0.65% | (4.00%) | (12.64%) | (14.07%) | (27.05%) | (74.88%) | (14.16%) | — | |
| 0.45% | (2.72%) | (8.70%) | (10.51%) | (19.67%) | (33.65%) | (41.96%) | — | |
ROIC |
0.98% | (1.26%) | (7.25%) | (8.03%) | (11.51%) | 0.72% | 0.00% | — |
Return on Tangible Assets |
2.97% | (23.01%) | (88.24%) | (85.74%) | (113.89%) | (521.39%) | 1,142.44% | — |
Average Days of Receivables |
24.53 | 38.46 | 43.36 | 42.83 | 41.60 | 42.29 | 32.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
26.83% | 29.02% | 38.91% | 43.98% | 64.98% | 19.27% | 19.32% | — |
Intangible Assets out of Total Assets |
0.67 | 0.70 | 0.72 | 0.71 | 0.78 | 0.91 | 0.82 | 0.00 |
Share Based Compensation of Revenue |
5.24% | 6.09% | 9.41% | 21.81% | 38.87% | 0.38% | 0.03% | — |
Graham Net Nets |
(0.10) | (0.13) | (0.16) | (0.26) | (0.04) | (0.08) | (0.08) | — |
Graham Number |
1.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
0.35% | (2.11%) | (6.46%) | (13.12%) | (9.65%) | (0.71%) | (0.71%) | — |
Free Cash Flow Yield |
4.05% | 3.07% | (1.98%) | (1.60%) | (2.73%) | (0.63%) | (0.63%) | — |
Revenue per Share |
3.69 | 3.30 | 2.87 | 2.42 | 2.04 | 1.25 | 0.57 | — |
Operating CF per Share |
0.38 | 0.28 | (0.05) | 0.15 | 0.03 | (0.03) | 0.05 | — |
Capex per Share |
(0.09) | (0.06) | (0.11) | (0.22) | (0.29) | (0.13) | (0.04) | — |
Free Cash Flow per Share |
0.29 | 0.23 | (0.16) | (0.07) | (0.26) | (0.15) | 0.01 | — |
Cash per Share |
0.64 | 0.41 | 0.21 | 0.31 | 0.45 | 0.06 | 0.01 | — |
Shareholders Equity per Share |
3.94 | 3.81 | 3.89 | 4.27 | 4.72 | 3.30 | (0.45) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
3.94 | 3.81 | 3.89 | 4.27 | 4.72 | 3.30 | (0.45) | — |
Free Cash Flow |
110.03 | 85.69 | (57.40) | (26.47) | (85.07) | (46.60) | 2.73 | — |
Working Capital |
164.24 | 83.62 | 22.86 | 57.22 | 149.77 | 0.36 | (27.58) | — |
Capital Expenditures |
(36.12) | (21.57) | (40.52) | (79.25) | (94.49) | (38.07) | (14.31) | — |
Net Current Asset Value |
(266.72) | (359.50) | (455.31) | (421.92) | (115.56) | (495.61) | (419.71) | — |
EV/EBIT |
113.25 | 0.00 | 0.00 | 0.00 | 0.00 | 789.14 | 789.14 | — |
Capex to Sales |
0.03 | 0.02 | 0.04 | 0.09 | 0.14 | 0.10 | 0.07 | — |
Price to Operating Income |
112.54 | 0.00 | 0.00 | 0.00 | 0.00 | 750.14 | 750.14 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.35 | 0.44 | 0.44 | 0.37 | 0.37 | 0.54 | 0.30 | — |
Cash ROIC |
5.41% | 4.56% | (3.21%) | (1.43%) | (4.60%) | (3.38%) | (3.27%) | — |
Accounts Receivable Turnover |
12.52 | 9.73 | 9.33 | 9.72 | 11.15 | 12.10 | 5.82 | — |
Accounts Payable Turnover |
144.15 | 118.74 | 77.94 | 47.10 | 42.67 | 45.55 | 25.02 | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
2.32 | 3.12 | 3.42 | 7.20 | 11.08 | 10.87 | 8.86 | — |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
113.76 | 128.60 | 113.14 | 88.47 | 59.89 | 31.17 | 36.50 | — |
Average Payables |
6.68 | 7.15 | 9.67 | 13.22 | 10.92 | 5.67 | 6.00 | — |
Average Assets |
2,161.12 | 2,114.13 | 2,141.92 | 2,050.49 | 1,748.42 | 925.26 | 140.39 | — |
Average Common Equity |
1,483.65 | 1,437.61 | 1,473.83 | 1,531.88 | 1,271.43 | 415.74 | 416.00 | — |
Columns are period end dates